Non-Fucosylated Anti-Human PDCD1 (AMP-514) Therapeutic Antibody (CAT#: BioBet-1494ZP) Datasheet

PDCD1

programmed cell death 1

This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases. [provided by RefSeq, Jul 2008]

PDCD1; programmed cell death 1; PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1; programmed cell death protein 1; protein PD-1; systemic lupus erythematosus susceptibility 2;

Plasma membrane, Extracellular region or secreted

Diseases associated with PDCD1 include Systemic Lupus Erythematosus 2 and Multiple Sclerosis.

Its related pathways are T cell receptor signaling pathway and Innate Immune System.

Antigens activate the inhibitory receptors of T cells and play a key role in inducing and maintaining autoimmune tolerance. When combined with ligands CD274/PDCD1L1 and CD273/PDCD1LG2, it delivers inhibitory signals. After the participation of t cell receptor (TCR), PDCD1 binds to CD3-TCR at the immune synapse and directly inhibits T cell activation (through similarity). Inhibition of t cell activation by recruiting PTPN11/SHP-2: After ligand binding, PDCD1 is phosphorylated in the ITSM motif, resulting in the recruitment of protein tyrosine phosphatase PTPN11/SHP-2, which mediates the deactivation of key TCR proximal signaling molecules Phosphorylation, such as ZAP70, PRKCQ/PKCtheta, and CD247/CD3zeta (by similarity). Tumors use pdcd1-mediated inhibition to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival. Interaction with CD274/PDCD1L1 can inhibit the effector function of cytotoxic T lymphocytes (CTLs). The blockade of the pdcd1-mediated pathway leads to the reversal of the phenotype of exhausted T cells and the normalization of anti-tumor response, which provides a theoretical basis for cancer immunotherapy.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

AMP-514

Mouse

Human

AMP-514 is an anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb). AMP-514 is currently in late-stage pre-clinical development with the aim of an investigational new drug (IND) filing before the end of 2013.

Cancer

Cancer